Ark Genomic Revolution ETF (ARKG)

N/A +N/A (N/A)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume N/A
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified.

Phone: 212-426-7040
Stocktradesmoon
Stocktradesmoon Jul. 30 at 8:49 AM
$ABCL $ABCL - interesting relative strength and holding bullish posture $IBB $ARKG $XBI
0 · Reply
Lakeview22
Lakeview22 Jul. 29 at 6:53 PM
$BFLY + Science Corp + Sanchez? The overlap is hard to ignore. Ultrasound-on-Chip meets the future of brain interfaces. 👀. $MDT $ARKG $AAPL
0 · Reply
madnessofcrowds
madnessofcrowds Jul. 28 at 9:31 PM
$ARKG green shoots in high beta bio land
0 · Reply
SternInvesting10
SternInvesting10 Jul. 28 at 2:10 PM
$NTLA beautiful weakness. This overvalued pig is finally unwinding. Scams getting exposed all over the place. $CRSP $ARKG
1 · Reply
B2iDigital
B2iDigital Jul. 24 at 9:57 PM
eXoZymes (Nasdaq: $EXOZ ) is among the first projects selected for the inaugural U.S. Department of Energy (DOE) Genesis Mission, a nationwide initiative bringing together national laboratories, universities, companies, and nonprofit organizations to accelerate scientific discovery. eXoZymes will work with Lawrence Berkeley National Laboratory to build AI-powered digital twins for its cell-free biomanufacturing platform. eXoZymes is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/exozymes The project extends the company’s AI work from enzyme engineering into manufacturing: • With Berkeley Lab, eXoZymes will develop hybrid digital twins that combine enzyme kinetics, reactor physics, and machine learning to identify optimal operating conditions before lab validation • The award provides access to the DOE Genesis Mission Platform: advanced AI models, AI agents, and high-performance computing • Subject to DOE award negotiations, the project is expected to carry about $747,000 in total funding, including about $147,000 for eXoZymes “We believe the next generation of biomanufacturing will be built at the intersection of artificial intelligence and digital insights into biology,” said Michael Heltzen, Chief Executive Officer of eXoZymes. Read the full release: https://exozymes.com/blog/genesis-mission-2026 eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to convert feedstocks into high-value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $DNLI, $TWST, $DNA, $ARKG
1 · Reply
SternInvesting10
SternInvesting10 Jul. 23 at 6:23 PM
$NTLA -93.08% over the last 5 years Cathie Wood the brightest most forward looking investor of our time… Making women look like shit She is an embarrassment and a fraud and has never admitted to her mistakes She’s a failure the likes we’ve never seen before $ARKG $ARKK $CRSP
1 · Reply
B2iDigital
B2iDigital Jul. 23 at 4:01 PM
eXoZymes (Nasdaq: $EXOZ ) frames itself as a repeatable engine for unlocking molecule classes. In a Webull webinar, Chief Commercial Officer Damien Perriman put cannabinoids forward as the next class after NCT. eXoZymes Inc. is a B2i Digital Featured Company. See the company's profile at https://b2idigital.com/exozymes-1 "This is not a single product company. It's a repeatable system for unlocking entire classes of molecules," Perryman told investors. Also from the presentation: • NCT is the first proof point and cannabinoids are the second, with cannabinoid receptors present on nearly every cell in the body • That reach spans metabolic, inflammatory, and neurological conditions, where access to rare cannabinoids has long been the bottleneck • eXoZymes says it can now produce rare and entirely new cannabinoids without intoxicating components, optimized toward specific therapeutic objectives Watch the full webinar: https://youtu.be/OmH3TaaMT20 eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to convert feedstocks into high-value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital's practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $DNLI, $TWST, $DNA, $ARKG
1 · Reply
JodieChristy
JodieChristy Jul. 22 at 10:25 PM
$ARKG breaking out of a multi-year Stage 1 base into a fresh Stage 2 uptrend! Trading near $39.00 intraday. The ETF is retesting key 2023 resistance levels alongside its first tap of the 10-week moving average. Genomics and biotech names are coiling up tightly, providing a classic pullback setup before the next leg higher. Techs look exceptionally clean here! "A lot of great opportunities if you know where to look. The battle map has been shared in the community! Are you going to miss out again?"
0 · Reply
EquityVoyager_1
EquityVoyager_1 Jul. 21 at 10:07 PM
Still feels like the market is overlooking the $ARKG Genomics ETF. This ETF continues to be a surprisingly useful risk-on/risk-off indicator. Right now, price is holding the weekly support band, suggesting broader market conditions may be starting to stabilize. The Meridian North Star entry from $30 remains active - no exit signal has appeared yet. For now, the setup stays intact, and I’ll continue monitoring the next major move closely.
0 · Reply
StockSilk
StockSilk Jul. 21 at 3:18 PM
$ARKG - ARK Genomic Revolution | ETF Technical Analysis https://stockpax.com/analysis/arkg/
0 · Reply
Latest News on ARKG
June's Top ETFs: Biotech & China Semiconductors Surge

Jul 1, 2026, 12:12 PM EDT - 4 weeks ago

June's Top ETFs: Biotech & China Semiconductors Surge

KSTR SBIO XBI BBC

Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC

Jun 16, 2026, 1:00 AM EDT - 6 weeks ago

Biotech IPO window is opening but big pharma M&A still sets the pace, top bankers tell CNBC

IBB XBI GSK NUVL NVS

Cathie Wood on DeepSeek, Nvidia, Stock Picks, China, AI

Jan 28, 2025, 6:00 PM EST - 1 year ago

Cathie Wood on DeepSeek, Nvidia, Stock Picks, China, AI

ARKB ARKF ARKK ARKQ ARKW

Best Healthcare ETFs To Buy Now

Oct 31, 2024, 2:03 PM EDT - 1 year ago

Best Healthcare ETFs To Buy Now

FXH IXJ VHT XBI XLV

BMO Transfers 3 BMO Mutual Fund ETF Series, Managed by ARK Investment Management, to Cboe Canada

Jun 14, 2024, 8:00 AM EDT - 2 years ago

BMO Transfers 3 BMO Mutual Fund ETF Series, Managed by ARK Investment Management, to Cboe Canada

Why investor appetite for commodity funds picked up despite ETF flows broadly seeing ‘pretty big drop' in April

May 2, 2024, 4:28 PM EDT - 2 years ago

Why investor appetite for commodity funds picked up despite ETF flows broadly seeing ‘pretty big drop' in April

AGG ARKB BCI BCIM BITO FBTC HODL

China-focused ETFs struggle amid fears of another regulatory ‘crackdown'

Jan 18, 2024, 3:23 PM EST - 2 years ago

China-focused ETFs struggle amid fears of another regulatory ‘crackdown'

ASHR BLOK CCEF CQQQ DXJ FXI JETS

How to Find the Best Biotech ETFs

Oct 30, 2023, 4:52 PM EDT - 2 years ago

How to Find the Best Biotech ETFs

IBB XBI

Cathie Wood Says ARK Funds Are Seeing Flows Coming Back

Jul 17, 2023, 4:57 PM EDT - 3 years ago

Cathie Wood Says ARK Funds Are Seeing Flows Coming Back

ARKF ARKK ARKW

Stocks that are cyclical are going to face severe challenges, says ARK Invest's Cathie Wood

Mar 21, 2023, 11:52 AM EDT - 3 years ago

Stocks that are cyclical are going to face severe challenges, says ARK Invest's Cathie Wood

ARKK ARKW

Stocktradesmoon
Stocktradesmoon Jul. 30 at 8:49 AM
$ABCL $ABCL - interesting relative strength and holding bullish posture $IBB $ARKG $XBI
0 · Reply
Lakeview22
Lakeview22 Jul. 29 at 6:53 PM
$BFLY + Science Corp + Sanchez? The overlap is hard to ignore. Ultrasound-on-Chip meets the future of brain interfaces. 👀. $MDT $ARKG $AAPL
0 · Reply
madnessofcrowds
madnessofcrowds Jul. 28 at 9:31 PM
$ARKG green shoots in high beta bio land
0 · Reply
SternInvesting10
SternInvesting10 Jul. 28 at 2:10 PM
$NTLA beautiful weakness. This overvalued pig is finally unwinding. Scams getting exposed all over the place. $CRSP $ARKG
1 · Reply
B2iDigital
B2iDigital Jul. 24 at 9:57 PM
eXoZymes (Nasdaq: $EXOZ ) is among the first projects selected for the inaugural U.S. Department of Energy (DOE) Genesis Mission, a nationwide initiative bringing together national laboratories, universities, companies, and nonprofit organizations to accelerate scientific discovery. eXoZymes will work with Lawrence Berkeley National Laboratory to build AI-powered digital twins for its cell-free biomanufacturing platform. eXoZymes is a B2i Digital Featured Company. See the company’s profile at https://b2idigital.com/exozymes The project extends the company’s AI work from enzyme engineering into manufacturing: • With Berkeley Lab, eXoZymes will develop hybrid digital twins that combine enzyme kinetics, reactor physics, and machine learning to identify optimal operating conditions before lab validation • The award provides access to the DOE Genesis Mission Platform: advanced AI models, AI agents, and high-performance computing • Subject to DOE award negotiations, the project is expected to carry about $747,000 in total funding, including about $147,000 for eXoZymes “We believe the next generation of biomanufacturing will be built at the intersection of artificial intelligence and digital insights into biology,” said Michael Heltzen, Chief Executive Officer of eXoZymes. Read the full release: https://exozymes.com/blog/genesis-mission-2026 eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to convert feedstocks into high-value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital’s practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $DNLI, $TWST, $DNA, $ARKG
1 · Reply
SternInvesting10
SternInvesting10 Jul. 23 at 6:23 PM
$NTLA -93.08% over the last 5 years Cathie Wood the brightest most forward looking investor of our time… Making women look like shit She is an embarrassment and a fraud and has never admitted to her mistakes She’s a failure the likes we’ve never seen before $ARKG $ARKK $CRSP
1 · Reply
B2iDigital
B2iDigital Jul. 23 at 4:01 PM
eXoZymes (Nasdaq: $EXOZ ) frames itself as a repeatable engine for unlocking molecule classes. In a Webull webinar, Chief Commercial Officer Damien Perriman put cannabinoids forward as the next class after NCT. eXoZymes Inc. is a B2i Digital Featured Company. See the company's profile at https://b2idigital.com/exozymes-1 "This is not a single product company. It's a repeatable system for unlocking entire classes of molecules," Perryman told investors. Also from the presentation: • NCT is the first proof point and cannabinoids are the second, with cannabinoid receptors present on nearly every cell in the body • That reach spans metabolic, inflammatory, and neurological conditions, where access to rare cannabinoids has long been the bottleneck • eXoZymes says it can now produce rare and entirely new cannabinoids without intoxicating components, optimized toward specific therapeutic objectives Watch the full webinar: https://youtu.be/OmH3TaaMT20 eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to convert feedstocks into high-value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital's practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $DNLI, $TWST, $DNA, $ARKG
1 · Reply
JodieChristy
JodieChristy Jul. 22 at 10:25 PM
$ARKG breaking out of a multi-year Stage 1 base into a fresh Stage 2 uptrend! Trading near $39.00 intraday. The ETF is retesting key 2023 resistance levels alongside its first tap of the 10-week moving average. Genomics and biotech names are coiling up tightly, providing a classic pullback setup before the next leg higher. Techs look exceptionally clean here! "A lot of great opportunities if you know where to look. The battle map has been shared in the community! Are you going to miss out again?"
0 · Reply
EquityVoyager_1
EquityVoyager_1 Jul. 21 at 10:07 PM
Still feels like the market is overlooking the $ARKG Genomics ETF. This ETF continues to be a surprisingly useful risk-on/risk-off indicator. Right now, price is holding the weekly support band, suggesting broader market conditions may be starting to stabilize. The Meridian North Star entry from $30 remains active - no exit signal has appeared yet. For now, the setup stays intact, and I’ll continue monitoring the next major move closely.
0 · Reply
StockSilk
StockSilk Jul. 21 at 3:18 PM
$ARKG - ARK Genomic Revolution | ETF Technical Analysis https://stockpax.com/analysis/arkg/
0 · Reply
oneklim
oneklim Jul. 21 at 4:37 AM
$ARKG let’s see how 35 line plays out
0 · Reply
FibonacciTrader_
FibonacciTrader_ Jul. 20 at 8:39 PM
$ARKG Some of the strongest non-tech themes from the recent rotation are starting to show signs of weakness. A few names are losing momentum, becoming wider and more volatile instead of holding key levels. Watching: $GH $LLY $XBI These groups had strong runs, but the price action is starting to show some pivot leakage. The big question now: are these just healthy pullbacks, or the beginning of a deeper reset?
0 · Reply
_MarketSurfer_
_MarketSurfer_ Jul. 20 at 8:00 PM
$ARKG Watching the rotation closely. Some of the strongest non-tech themes that benefited from the recent market shift are starting to show signs of weakness. The charts are getting wider and looser, with some names failing to hold the levels where buyers should be stepping in. $GH $LLY $XBI These are still important groups to watch, but the near-term price action needs improvement. Rotation can change quickly. The key is following where money is actually staying, not where it was yesterday.
0 · Reply
StocktwitsNews
StocktwitsNews Jul. 20 at 5:18 AM
ATAI Stock Slips After Blockbuster Week: Cathie Wood Calls $3.8B Lilly Deal ‘Well-Deserved’ Return For Shareholders $ATAI $LLY $ARKG https://stocktwits.com/news/equity/markets/atai-cathie-wood-lilly-deal-well-deserved-return-shareholders/cZZLrZTR7MA
0 · Reply
B2iDigital
B2iDigital Jul. 17 at 9:10 PM
A platform that works in the lab is not yet a business. In a Webull webinar, eXoZymes (Nasdaq: $EXOZ ) pointed to a scale-up run it says clears that bar. eXoZymes Inc. is a B2i Digital Featured Company. See the company's profile at https://b2idigital.com/exozymes-1 Perryman framed the milestone directly: "Many technologies work in the lab, but many also fail at scale. What we've demonstrated here is that the system translates from concept to industrial conditions, and that's what turns this from a science into a viable business." The webinar detailed the run: • The company ran a 100-liter pilot at the end of last year, reporting 99% conversion of raw material to target product and 99.6% purity • The run took place at a third party after eXoZymes tech-transferred its process, operating conditions, and enzyme cascades • Management called this an operational process rather than a theoretical one, and an inflection point for investors Watch the full webinar: https://youtu.be/OmH3TaaMT20 eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to convert feedstocks into high-value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital's practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $DNLI, $TWST, $DNA, $ARKG
1 · Reply
madnessofcrowds
madnessofcrowds Jul. 16 at 6:58 PM
$ARKG low volume sell off
0 · Reply
PorkchopSquats
PorkchopSquats Jul. 16 at 4:30 PM
$ARKG I’m just trying to find a silver lining here, this shit sucks lmfao. @Thelonius_Stonk hopium confirmation plz. $CRSP $NTLA $PRME $BEAM
2 · Reply
_ivan
_ivan Jul. 16 at 6:48 AM
$ARKG $DNA $DNLI $EXOZ $TWST
0 · Reply
TrendStalker_
TrendStalker_ Jul. 15 at 8:10 PM
$ARKG monthly chart is showing an interesting technical setup. The last time price broke above the 2 linear Gann level, the stock entered a powerful parabolic move and eventually reached the 10 linear level. Now, price has broken above the 2 level again. The big question: can history repeat? Currently, $ARKG is consolidating near the 3 linear Gann level around $44.82. This area could become a key test for whether momentum continues or the breakout loses strength. Watching how price reacts here will be critical.
1 · Reply
TalkMarkets
TalkMarkets Jul. 15 at 11:30 AM
Has Wall Street Gotten #Meta Wrong? $META Also Discusses: $ARKG $DRAM.X $NVDA $SMH https://talkmarkets.com/article/meta-cheap-1784108396
0 · Reply
B2iDigital
B2iDigital Jul. 14 at 5:15 PM
eXoZymes (Nasdaq: $EXOZ ) is targeting metabolic dysfunction a layer deeper than appetite. In a recent Webull webinar, Chief Commercial Officer Damien Perriman walked investors through NCT, the company's first proof point. eXoZymes Inc. is a B2i Digital Featured Company. See the company's profile at https://b2idigital.com/exozymes-1 "It is fundamentally different from GLP-1 drugs," Perryman said. "GLP-1s reduce appetite, whereas NCT and its activation of HNF4 alpha improves mitochondrial biogenesis and mitochondrial activity, essentially improving how the body burns fat." From the same segment: • NCT activates HNF4 alpha, a master metabolic control switch, rather than acting on a single downstream symptom • In controlled preclinical models on identical diets, eXoZymes reported 30% to 40% less weight gain in the mouse population • The company also observed improved mitochondrial function and reduced liver fat, consistent with hitting a central regulatory pathway Watch the full webinar: https://youtu.be/OmH3TaaMT20 eXoZymes Inc. is a Los Angeles, California based biotechnology company developing cell-free biomanufacturing technology that uses AI-engineered enzymes to convert feedstocks into high-value compounds, with applications across nutraceuticals and pharmaceuticals. Learn more at https://exozymes.com. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: David Shapiro, Chief Executive Officer of B2i Digital, personally purchased in the open market and currently owns shares of unrestricted EXOZ stock, in line with B2i Digital's practice of investing alongside its Featured Companies. See the complete Disclosure at https://b2idigital.com/disclaimer. B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $DNLI, $TWST, $DNA, $ARKG
1 · Reply
TalkMarkets
TalkMarkets Jul. 14 at 4:21 PM
SMID Biotech Stocks Were Cruising To New Highs Until Friday’s Speed Bump $ABBV $ADPT $AMRX $ARKG $BAX https://talkmarkets.com/article/smid-biotech-stocks-were-cruising-to-new-highs-until-fridays-speed-bump-1784045167
0 · Reply